Caribou Biosciences, Inc. (Nasdaq: CRBU), a prominent player in the clinical-stage CRISPR genome-editing biopharmaceutical sector, has announced an upcoming webcast scheduled for 8:00 AM ET on Monday, November 3, 2025. The event will focus on new data emerging from two significant clinical trials involving allogeneic CAR-T cell therapies.
During the webcast, Caribou will provide insights from the ANTLER phase 1 clinical trial, which assesses vispacabtagene regedleucel (vispa-cel; previously known as CB-010). This therapy targets anti-CD19 CAR-T cells and is being evaluated for its effectiveness in treating patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
Furthermore, the presentation will also feature initial clinical data from the CaMMouflage Phase 1 clinical trial, which investigates CB-011, an allogeneic anti-BCMA CAR-T cell therapy aimed at patients with relapsed or refractory multiple myeloma.
In addition to the trial updates, the company plans to discuss the anticipated design of its pivotal phase 3 trial for vispa-cel and outline the next steps for advancing the clinical development of CB-011.
A live stream of the presentation will be available on the Events page of Caribou”s website, and an archived version of the webcast will be accessible for 30 days following the event.
